{"id":"ligustrazine-by-intravenously-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal discomfort"},{"rate":null,"effect":"Bleeding risk (minor)"}]},"_chembl":{"chemblId":"CHEMBL1939729","moleculeType":"Small molecule","molecularWeight":"172.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ligustrazine (tetramethylpyrazine) is an alkaloid derived from Ligusticum wallichii that works primarily as an antiplatelet and vasodilatory agent. It reduces platelet aggregation, decreases blood viscosity, and improves microcirculatory blood flow, making it useful in conditions characterized by poor circulation and thrombotic risk. The drug also has antioxidant properties that may contribute to its therapeutic effects.","oneSentence":"Ligustrazine inhibits platelet aggregation and improves microcirculation by reducing blood viscosity and enhancing blood flow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:15.495Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Cerebral infarction"},{"name":"Peripheral vascular disease"},{"name":"Diabetic angiopathy"}]},"trialDetails":[{"nctId":"NCT05942352","phase":"PHASE4","title":"Clinical Study of Ligustrazine in Treating Alcohol Addiction","status":"UNKNOWN","sponsor":"Shenzhen Kangning Hospital","startDate":"2023-07-28","conditions":"Alcohol Abuse, Arteriosclerosis","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tetramethylpyrazine by intravenously administration"],"phase":"marketed","status":"active","brandName":"Ligustrazine by intravenously administration","genericName":"Ligustrazine by intravenously administration","companyName":"Shenzhen Kangning Hospital","companyId":"shenzhen-kangning-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ligustrazine inhibits platelet aggregation and improves microcirculation by reducing blood viscosity and enhancing blood flow. Used for Acute ischemic stroke, Cerebral infarction, Peripheral vascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}